FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Immunomedics Inc
Immunomedics Inc_20100114
Immunomedics Inc_20100121

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Immunomedics, Inc. patents


      
Recent patent applications related to Immunomedics, Inc.. Immunomedics, Inc. is listed as an Agent/Assignee. Note: Immunomedics, Inc. may have other listings under different names/spellings. We're not affiliated with Immunomedics, Inc., we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunomedics, Inc.-related inventors


Search recent Press Releases: Immunomedics, Inc.-related press releases
Count Application # Date Immunomedics, Inc. patents (updated weekly) - BOOKMARK this page
12015005743202/26/15 new patent  Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
22015003868602/05/15Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
32015001851601/15/15Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
42014037717312/25/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
52014037717712/25/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
62014037728712/25/14Anti-trop-2 antibody-drug conjugates and uses thereof
72014036992712/18/14Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
82014028686009/25/14Immunoconjugates with an intracellularly-cleavable linkage
92014028686109/25/14Rs7 antibodies
102014023420908/21/14Chimeric and humanized anti-histone antibodies
112014022717808/14/14Humanized anti-hla-dr antibodies
122014022717908/14/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
132014022718008/14/14Antibody-sn-38 immunoconjugates with a cl2a linker
142014022854108/14/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
152014021991408/07/14Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
162014021995608/07/14Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
172014021242507/31/14Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
182014019335907/10/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
192014017829406/26/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
202014017006506/19/14Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
212014015427306/05/14Anthracycline-antibody conjugates for cancer therapy
222014014738205/29/14Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
232014014092405/22/14Humanized l243 antibodies
242014012003505/01/14Rs7 antibodies
252014011286404/24/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
262014011286504/24/14Anti-cd19 antibodies
272014010581904/17/14In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
282014009925804/10/14Camptothecin-binding moiety conjugates
292014008683003/27/14Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
302014008683203/27/14Delivery system for cytotoxic drugs by bispecific antibody pretargeting
312014007962903/20/14Class i anti-cea antibodies and uses thereof
322014005806702/27/14Immunoconjugates with an intracellularly-cleavable linkage
332014004463902/13/14Antibody therapy
342014004464002/13/14Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
352014003754302/06/14Anti-pancreatic cancer antibodies
362014003826102/06/14Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
372014003828402/06/14Mammalian cell lines for increasing longevity and protein yield from a cell culture
382014001716801/16/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
392014001719701/16/14Anti-cd19 antibodies
402014000407801/02/14Immunoconjugates with an intracellularly-cleavable linkage
412013031582111/28/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
422013030917711/21/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
432013021656108/22/13Immunoconjugates with an intracellularly-cleavable linkage
442013020935608/15/13Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
452013021104408/15/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
462013017749807/11/13Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
472013017752607/11/13Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
482013017106407/04/13Anti-cd74 immunoconjugates and methods of use
492013017106507/04/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
502013017117607/04/13Anthracycline-antibody conjugates for cancer therapy
512013016421406/27/13Antibody-based depletion of antigen-presenting cells and dendritic cells
522013016478306/27/13Mammalian cell lines for increasing longevity and protein yield from a cell culture
532013015669106/20/13Antibody therapy
542013014278706/06/13Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
552013014329606/06/13Delivery system for cytotoxic drugs by bispecific antibody pretargeting
562013012191305/16/13Anti-cd19 antibodies
572013012347305/16/13Bispecific antibody targeting a complement factor or complement regulatory protein
582013009503404/18/13Anti-cd74 immunoconjugates and methods
592013009045804/11/13Immunoconjugates with an intracellularly-cleavable linkage
602013007818203/28/13Structural variants of antibodies for improved therapeutic characteristics
612013007826303/28/13Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
622013007132003/21/13Immunotherapy of autoimmune disorders using antibodies which target b-cells
632013007140603/21/13Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
642013007265903/21/13Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
652013003986102/14/13Dye conjugated peptides for fluorescent imaging
662013003449202/07/13Class i anti-cea antibodies and uses thereof
672012032856412/27/12Camptothecin-binding moiety conjugates
682012032863412/27/12Immunoconjugates with an intracellularly-cleavable linkage
692012032155312/20/12Ultrafiltration concentration of allotype selected antibodies for small-volume administration
702012028217811/08/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
712012027610011/01/12Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
722012023095309/13/12Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
732012021496908/23/12Methods and compositions for f-18 labeling of proteins, peptides and other molecules
742012019632608/02/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
752012018954207/26/12Anti-cd19 antibodies
762012018347207/19/12Immunotherapy of b-cell malignancies using anti-cd22 antibodies
772012018355007/19/12Therapeutic using a bispecific antibody
782012014908506/14/12Fusion proteins containing recombinant cytotoxic rnases
792012014137206/07/12Rs7 antibodies
802012014137506/07/12Anti-mucin antibodies for early detection and treatment of pancreatic cancer
812012013492005/31/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
822012011455605/10/12Immunotherapy of autoimmune disorders using antibodies which target b-cells
832012010723505/03/12Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
842012008829904/12/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
852012008261704/05/12Immunoconjugates with an intracellularly-cleavable linkage
862012007672703/29/12In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
872012006399303/15/12Therapeutic and diagnostic conjugates for use with multispecific antibodies
882012003979702/16/12Antibody therapy
892012004043102/16/12Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
902012003418502/09/12Anti-cd20 antibodies and fusion proteins therof and methods of use
912011031153112/22/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
922011030563112/15/11Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
932011030006612/08/11Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
942011029351312/01/11Immunoconjugates with an intracellularly-cleavable linkage
952011028691811/24/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
962011028080111/17/11Methods and compositions for f-18 labeling of proteins, peptides and other molecules
972011027470411/10/11Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
982011025605310/20/11Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
992011024384110/06/11Antibody-based depletion of antigen-presenting cells and dendritic cells
1002011024454610/06/11Internalizing anti-cd74 antibodies and methods of use
1012011023630409/29/11Structural variants of antibodies for improved therapeutic characteristics
1022011023640409/29/11Methods for protein expression in mammalian cells in serum-free medium
1032011022940709/22/11Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1042011022364509/15/11Multivalent carriers of bi-specific antibodies
1052011019502308/11/11Internalizing anti-cd74 antibodies and methods of use
1062011018908508/04/11Antibody therapy
1072011018926808/04/11Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1082011017112607/14/11Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
1092011016507207/07/11Detection of early-stage pancreatic adenocarcinoma
1102011016507307/07/11Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1112011011701005/19/11Methods and compositions for administering therapeutic and diagnostic agents
1122011011710505/19/11Method of treating immune disease using b-cell antibodies
1132011011085405/12/11Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1142011007623303/31/11Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1152011007015503/24/11Anti-cd74 immunoconjugates and methods
1162011007015603/24/11Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
1172011006465303/17/11Class i anti-cea antibodies and uses thereof
1182011005248903/03/11Anti-cd19 antibodies
1192010031116212/09/10Mammalian cell lines for increasing longevity and protein yield from a cell culture
1202010028490611/11/10Internalizing anti-cd74 antibodies and methods of use
1212010027263610/28/10Anti-cd74 immunoconjugates and methods of use
1222010026649610/21/10Anti-cd74 immunoconjugates and methods of use
1232010026649710/21/10Internalizing anti-cd74 antibodies and methods of use
1242010023377909/16/10Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1252010022688409/09/10Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
1262010022117509/02/10Antibody therapy
1272010022117709/02/10Rs7 antibodies
1282010021666208/26/10Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1292010020296108/12/10D-amino acid peptides
1302010019626608/05/10Humanized anti-hla-dr antibodies
1312010019626708/05/10Humanized l243 antibodies
1322010019698908/05/10Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1332010018964107/29/10Novel strategies for improved cancer vaccines
1342010015880206/24/10Chimeric, human and humanized anti-csap monoclonal antibodies
1352010015880306/24/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1362010013662606/03/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1372010010458904/29/10Immunoconjugates with an intracellularly-cleavable linkage
1382010007484003/25/10Anthracycline-antibody conjugates for cancer therapy
1392010006813603/18/10Anti-cd19 antibodies
1402010004054102/18/10Structural variants of antibodies for improved therapeutic characteristics
1412010003473802/11/10Structural variants of antibodies for improved therapeutic characteristics
1422010001504601/21/10Camptothecin-binding moiety conjugates
1432010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1442010000885501/14/10Production and use of novel peptide-based agents with bispecific antibodies
1452010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1462009030458012/10/09Anti-pancreatic cancer antibodies
1472009029903312/03/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1482009029109311/26/09Immunoconjugates with an intracellularly-cleavable linkage
1492009028575211/19/09Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
1502009027464911/05/09Bispecific antibody point mutations for enhancing rate of clearance
1512009025273110/08/09Multivalent carriers of bi-specific antibodies
1522009025317910/08/09Mammalian cell lines for increasing longevity and protein yield from a cell culture
1532009024613010/01/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1542009024613110/01/09Production and use of novel peptide-based agents for use with bi-specific antibodies
1552009024621410/01/09Fusion proteins containing recombinant cytotoxic rnases
1562009023875709/24/09Methods and compositions for administering therapeutic and diagnostic agents
1572009024003709/24/09Humanized antibodies and methods of humanizing antibodies
1582009018597407/23/09Chimeric, human and humanized anti-granulocyte antibodies and methods of use
1592009015516606/18/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1602009015525306/18/09Anti-cd20 antibodies and fusion proteins therof and methods of use
1612009011114304/30/09Methods and compositions for mammalian cell lines for transfection and protein expression in serum-free medium
1622009009259804/09/09Antibody therapy
1632010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1642010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunomedics, Inc. in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunomedics, Inc. with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE